Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR3824 Monotherapy in Chinese Patients with Type 2 Diabetes
NCT02366351Phase 1Unknown
- Sponsor
- Hengrui
- Start
- Feb 2015
- Primary completion
- Jan 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of henagliflozin in type 2 diabetes mellitus (T2DM) (4 arms), sponsored by Hengrui. Primary endpoints: Adjusted Mean Change in HbA1c Levels at 12 weeks and Number of volunteers with adverse events at 12 weeks. Status: unknown.
02
Drugs
henagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02366351.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02366351.